Goldstein David J, Lu Yili, Detke Michael J, Hudson James, Iyengar Smriti, Demitrack Mark A
Department of Psychitry adn the Department of Pharmacology adn toxicology, Indiana Unibersity School of Medicine, Indianapolis, USA.
Psychosomatics. 2004 Jan-Feb;45(1):17-28. doi: 10.1176/appi.psy.45.1.17.
Painful physical symptoms are common features of major depressive disorder and may be the presenting complaints in primary care settings. The effect of the dual serotonin (5-HT) and norepinephrine reuptake inhibitor duloxetine on emotional and painful physical symptoms in outpatients with major depressive disorder was evaluated in three randomized, double-blind, placebo-controlled trials. The trials' primary objective was to evaluate the effect of duloxetine on mood, and subjects were not enrolled on the basis of presence, type, or severity of pain. However, the pain-relieving effects of duloxetine were evaluated by a priori defined analyses of results from a visual analogue scale and the Somatic Symptom Inventory. Compared with placebo, duloxetine was associated with significant reduction in pain severity. The authors concluded that duloxetine reduces the painful physical symptoms of depression.
疼痛性躯体症状是重度抑郁症的常见特征，可能是初级保健机构中患者的主要就诊主诉。在三项随机、双盲、安慰剂对照试验中，评估了5-羟色胺（5-HT）和去甲肾上腺素双重再摄取抑制剂度洛西汀对重度抑郁症门诊患者情绪和疼痛性躯体症状的影响。这些试验的主要目的是评估度洛西汀对情绪的影响，受试者并非基于疼痛的存在、类型或严重程度入选。然而，通过对视觉模拟量表和躯体症状量表结果进行预先定义的分析来评估度洛西汀的止痛效果。与安慰剂相比，度洛西汀可显著降低疼痛严重程度。作者得出结论，度洛西汀可减轻抑郁症患者的疼痛性躯体症状。
